Statin use vs. average non-HDL cholesterol levels in China

China: Statin use vs. average non-HDL cholesterol levels was 3.3 in 2018. ▲ Rising

Latest (2018)
3.3
Change on year
unchanged
World rank
95th
of 191 countries
All-time high
3.3
in 2008
All-time low
2.8
in 1980
Years of data
39
1980–2018

Statin use vs. average non-HDL cholesterol levels in China, 1980–2018

01231980199920181980: 2.81981: 2.81982: 2.81983: 2.81984: 2.91985: 2.91986: 2.91987: 2.91988: 31989: 31990: 31991: 31992: 31993: 31994: 3.11995: 3.11996: 3.11997: 3.11998: 3.11999: 3.12000: 3.12001: 3.12002: 3.22003: 3.22004: 3.22005: 3.22006: 3.22007: 3.22008: 3.32009: 3.32010: 3.32011: 3.32012: 3.32013: 3.32014: 3.32015: 3.32016: 3.32017: 3.32018: 3.3

Source: World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data.

Analysis

The most recent figure for statin use vs. average non-hdl cholesterol levels in China is 3.3, measured in 2018. That is the highest value across all 39 years on record.

That represents a change of unchanged over ten years.

Over the whole period, statin use vs. average non-hdl cholesterol levels in China peaked at 3.3 in 2008 and was at its lowest, 2.8, in 1980.

That places China 95th out of 191 countries with data for 2018, putting it in the middle of the range.

The long-run direction has been consistently rising across the 39 years of available data.

Averages by decade

DecadeAverage LowestHighest Years
1980s 2.88 2.8 3 10
1990s 3.06 3 3.1 10
2000s 3.2 3.1 3.3 10
2010s 3.3 3.3 3.3 9

Countries ranked near China

  1. 95 Algeria 3.3 compare
  2. 95 Azerbaijan 3.3 compare
  3. 95 Bahrain 3.3 compare
  4. 95 Barbados 3.3 compare
  5. 95 Bolivia 3.3 compare
  6. 95 Bosnia and Herzegovina 3.3 compare
  7. 95 Cambodia 3.3 compare
  8. 95 Cuba 3.3 compare
  9. 95 Egypt 3.3 compare
  10. 95 Ghana 3.3 compare
  11. 95 Kiribati 3.3 compare
  12. 95 Laos 3.3 compare
  13. 95 Marshall Islands 3.3 compare
  14. 95 Netherlands 3.3 compare
  15. 95 Spain 3.3 compare
  16. 95 Sri Lanka 3.3 compare
  17. 95 Suriname 3.3 compare
  18. 95 Turkey 3.3 compare
  19. 95 Turkmenistan 3.3 compare
  20. 95 United Kingdom 3.3 compare
  21. 95 United States 3.3 compare

See the full ranking of 191 places →

More reference data data for China

All data for China →

Frequently asked questions

What is statin use vs. average non-hdl cholesterol levels in China?
Statin use vs. average non-hdl cholesterol levels in China was 3.3 in 2018, according to World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data.
What is the highest statin use vs. average non-hdl cholesterol levels recorded in China?
The highest recorded value was 3.3 in 2008.
What is the lowest statin use vs. average non-hdl cholesterol levels recorded in China?
The lowest recorded value was 2.8 in 1980.
How does China rank for statin use vs. average non-hdl cholesterol levels?
China ranks 95th out of 191 countries with data for 2018.
Is statin use vs. average non-hdl cholesterol levels rising or falling in China?
Over the last ten years it is unchanged. The long-run trend across the full record is rising.
Where does this China data come from?
The figures come from World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as part of Statin use vs. average non-HDL cholesterol levels. Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 39 observations, free to reuse under CC BY 4.0 (Our World in Data).

About this data

Indicator
Statin use vs. average non-HDL cholesterol levels
Source
World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data
Licence
CC BY 4.0 (Our World in Data)
Coverage
191 places, 7,449 data points, 1980–2018
Last refreshed

The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.